Prazosin does not alter levels of plasma lipids, glucose, and insulin.
In a double-blind, randomized, cross-over study involving 15 mild hypertensive patients, the effects of prazosin (5.7 mg/day) and placebo on plasma levels of lipids, lipoproteins, glucose, and insulin were compared. After 5 weeks of treatment, prazosin had not significantly altered the mean levels of plasma cholesterol, phospholipids, and triglycerides in the high-density lipoprotein or low-density lipoprotein plus very low-density lipoprotein subfractions. Fasting and postload plasma levels of glucose and insulin were also unaffected.
F
F
Cambien
P F
PF
Plouin
D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007328:Insulin / Q000097:blood*; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D011224:Prazosin / Q000627:therapeutic use*; D011674:Pulse / Q000187:drug effects; D011799:Quinazolines / Q000627:therapeutic use*; D011897:Random Allocation
D001786:Blood Glucose; D007328:Insulin; D008055:Lipids; D008074:Lipoproteins; D011799:Quinazolines; D011224:Prazosin